Current management of diabetic tractional retinal detachments

Twenty-five percent of diabetes-related vision loss stems from complications of proliferative diabetic retinopathy (PDR). Panretinal photocoagulation has been the preferred treatment of high-risk PDR for decades and more recently intravitreal injections of drugs that inhibit the actions of vascular...

Full description

Bibliographic Details
Main Authors: Michael W Stewart, David J Browning, Maurice B Landers
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2018-01-01
Series:Indian Journal of Ophthalmology
Subjects:
Online Access:http://www.ijo.in/article.asp?issn=0301-4738;year=2018;volume=66;issue=12;spage=1751;epage=1762;aulast=Stewart
_version_ 1818308621790871552
author Michael W Stewart
David J Browning
Maurice B Landers
author_facet Michael W Stewart
David J Browning
Maurice B Landers
author_sort Michael W Stewart
collection DOAJ
description Twenty-five percent of diabetes-related vision loss stems from complications of proliferative diabetic retinopathy (PDR). Panretinal photocoagulation has been the preferred treatment of high-risk PDR for decades and more recently intravitreal injections of drugs that inhibit the actions of vascular endothelial growth factor have become popular. But despite these treatments PDR may progress uncontrollably to advanced pathologies such as traction retinal detachments (TRDs), combined traction/rhegmatogenous retinal detachments (TRD/RRDs), vitreous hemorrhages, rubeosis iridis, and traction maculopathies, which produce mild-to-severe loss of vision. TDR have long been the most common indication for PDR-related vitreoretinal surgery. Vitrectomy surgery is indicated for recent (<6 months duration) TRD involving the macula, progressive TRD that threatens the macula, and recent data suggest that chronic macula-involving TRDs (>6 months duration) may also benefit. Combined TRD/RRD represents a particularly challenging surgical condition but advances in surgical instrumentation, dissection techniques, and post-operative tamponade have produced excellent success rates. The recent development of small-gauge vitrectomy systems has persuaded most surgeons to switch platforms since these appear to produce shorter surgical times and quicker post-operative recoveries. Pre-operative injections of bevacizumab are frequently administered for persistent neovascularization to facilitate surgical dissection of pre-retinal fibrosis and reduce the incidence of post-operative hemorrhages. Recent trends toward earlier surgical intervention and expanded indications are likely to continue as surgical instrumentation and techniques are further developed.
first_indexed 2024-12-13T07:17:11Z
format Article
id doaj.art-f45a10b6d418401fb8d54740268056c8
institution Directory Open Access Journal
issn 0301-4738
1998-3689
language English
last_indexed 2024-12-13T07:17:11Z
publishDate 2018-01-01
publisher Wolters Kluwer Medknow Publications
record_format Article
series Indian Journal of Ophthalmology
spelling doaj.art-f45a10b6d418401fb8d54740268056c82022-12-21T23:55:32ZengWolters Kluwer Medknow PublicationsIndian Journal of Ophthalmology0301-47381998-36892018-01-0166121751176210.4103/ijo.IJO_1217_18Current management of diabetic tractional retinal detachmentsMichael W StewartDavid J BrowningMaurice B LandersTwenty-five percent of diabetes-related vision loss stems from complications of proliferative diabetic retinopathy (PDR). Panretinal photocoagulation has been the preferred treatment of high-risk PDR for decades and more recently intravitreal injections of drugs that inhibit the actions of vascular endothelial growth factor have become popular. But despite these treatments PDR may progress uncontrollably to advanced pathologies such as traction retinal detachments (TRDs), combined traction/rhegmatogenous retinal detachments (TRD/RRDs), vitreous hemorrhages, rubeosis iridis, and traction maculopathies, which produce mild-to-severe loss of vision. TDR have long been the most common indication for PDR-related vitreoretinal surgery. Vitrectomy surgery is indicated for recent (<6 months duration) TRD involving the macula, progressive TRD that threatens the macula, and recent data suggest that chronic macula-involving TRDs (>6 months duration) may also benefit. Combined TRD/RRD represents a particularly challenging surgical condition but advances in surgical instrumentation, dissection techniques, and post-operative tamponade have produced excellent success rates. The recent development of small-gauge vitrectomy systems has persuaded most surgeons to switch platforms since these appear to produce shorter surgical times and quicker post-operative recoveries. Pre-operative injections of bevacizumab are frequently administered for persistent neovascularization to facilitate surgical dissection of pre-retinal fibrosis and reduce the incidence of post-operative hemorrhages. Recent trends toward earlier surgical intervention and expanded indications are likely to continue as surgical instrumentation and techniques are further developed.http://www.ijo.in/article.asp?issn=0301-4738;year=2018;volume=66;issue=12;spage=1751;epage=1762;aulast=StewartDiabetesdiabetic retinopathytractional retinal detachmentvitrectomy
spellingShingle Michael W Stewart
David J Browning
Maurice B Landers
Current management of diabetic tractional retinal detachments
Indian Journal of Ophthalmology
Diabetes
diabetic retinopathy
tractional retinal detachment
vitrectomy
title Current management of diabetic tractional retinal detachments
title_full Current management of diabetic tractional retinal detachments
title_fullStr Current management of diabetic tractional retinal detachments
title_full_unstemmed Current management of diabetic tractional retinal detachments
title_short Current management of diabetic tractional retinal detachments
title_sort current management of diabetic tractional retinal detachments
topic Diabetes
diabetic retinopathy
tractional retinal detachment
vitrectomy
url http://www.ijo.in/article.asp?issn=0301-4738;year=2018;volume=66;issue=12;spage=1751;epage=1762;aulast=Stewart
work_keys_str_mv AT michaelwstewart currentmanagementofdiabetictractionalretinaldetachments
AT davidjbrowning currentmanagementofdiabetictractionalretinaldetachments
AT mauriceblanders currentmanagementofdiabetictractionalretinaldetachments